Kinetigen, Inc., a specialty pharmaceutical consulting firm with global reach, has announced that the company is changing its name to Nuventra Pharma Sciences, Inc., effective immediately. All management, scientific, and operational components of Nuventra remain the same as under Kinetigen, including the consulting firm’s focus on clinical pharmacology, pharmacokinetics, and pharmacometrics.
The change to Nuventra is the result of a trademark dispute for the company’s prior name of Kinetigen. Although management strongly disagrees with the claims madein the trademark dispute, they have chosen to rename the organization rather than be distracted by a prolonged legal action.
“We continue to execute our growth strategy that has solidified our position as the ‘go-to’ resource for clinical pharmacology, pharmacokinetics, and pharmacometrics in the pharmaceutical industry” said Geoffrey Banks, Ph.D., Nuventra CEO, adding, “We plan to significantly increase our efforts to reach pharmaceutical and biotech companies needing the type of expertise and services that our industry-leading consultants can provide.”
The consulting firm has grown significantly since it was founded in 2008 and has added senior consultants such as David Y. Mitchell, Ph.D., immediate past President of the American Association of Pharmaceutical Scientists (AAPS), Mark Sale, MD, former Global Director of Modeling and Simulation at GlaxoSmithKline (GSK), and Mark Bush, Ph.D., former Director of Pharmacokinetics at GSK. In addition, Nuventra is becoming a leader in pharmacometrics, population PK, and modeling of exposure-response relationships.
“Nuventra is making a significant investment in pharmacometrics to provide superior population PK and model-based drug development services to its clients” said Mark Sale, MD, Nuventra Vice President of Modeling and Simulation, adding, “Pharmacometrics is a key part of our growth strategy.”